Navigation Links
United Therapeutics Reports Third Quarter 2007 Financial Results
Date:11/1/2007

- Record Total Revenues of $59.0 Million, Up 46 Percent Over Third Quarter

2006 - Third Quarter EPS of $0.70 per Basic Share, or $0.66 per Diluted Share - Third Quarter EBITDASO of $1.26 per Basic Share, or $1.19 per Diluted

Share

SILVER SPRING, Md., Nov. 1 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended September 30, 2007.

Total revenues for the third quarter of 2007 were $59.0 million, up 46% from $40.4 million for the third quarter of 2006. Pro forma earnings corresponding to our Company-wide Milestone measuring GAAP earnings before income taxes, depreciation, amortization and stock option expenses (EBITDASO), were $26.6 million for the third quarter of 2007, up 35% from $19.7 million for the third quarter of 2006. Net income for the third quarter of 2007 was $14.8 million, or $0.70 per basic share, up 74% from $8.5 million, or $0.37 per basic share, in the third quarter of 2006. Gross margins from sales were $52.2 million in the third quarter of 2007, as compared to $36.2 million in the third quarter of 2006. The increases in revenues and gross margins resulted primarily from growth in sales of our lead product, Remodulin.

"It is pretty gratifying for us to be on the line of approximately 40% annual growth in revenues for almost five years now," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "Our trailing twelve month revenues of $196.9 million are 37% above that of the preceding period. Plus, this is our 13th profitable quarter overall, and our 14th straight profitable quarter disregarding
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Inacom Education earns Wisconsin membership in United Training
2. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , REYKJAVIK, Iceland, Novem...Inc. (Nasdaq: DCGN ) today announced the approval ...ruptcy Court for the District of Delaware,(the "Ba...ry petition for,relief under Chapter 11 of the Uni...rt. , The orders issued by the Bankruptcy...
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asi... Food & Drug Administration (SFDA) has approve...or its oral insulin project,(Nodlin), an innovativ...approval allows Biolaxy to initiate its first phas...der characteristic of high blood glucose and poor,...
(Date:11/24/2009)... , , Primary efficacy endpoint has been m...nt endometrial cancer, , QUEBEC CITY, Nov. 24...ASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global...erapy and oncology, today announced positive effic...totoxic peptide conjugate, AEZS-108 (formerly AN-1...
(Date:11/24/2009)... , SAN DIEGO, Nov. 24, 2009 /PRNewswire-F... ARNA ) announced today that the company is sche...Health Care Conference on December 1, 2009 at 11:3...e New York Palace Hotel in New York City. Jack Lie...is scheduled to provide an overview of the company...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
...Preliminary Data Show Seven of 17 Evaluable Patien...Four Treatment Cycles- , , TUSTIN, Calif., Feb. 4...) today reported that its lead product candidate b...in the first stage of its ongoing Phase II clinica...r (NSCLC). The open-label, Simon two-stage study ...
...ELGIUM, Wis., Feb. 4 Mach One Corporation (Pink S...h company that develops biotechnology based soluti...e agricultural and consumer markets, announced tod...quire Ceres Organic Harvest, Inc. an organic grain... to the food, feed and dairy industries. , , Unde...
... New Shape Memory Alloy Sta...fits of Shape Memory Alloys. The Kit is a hands on...d provides both a comprehensive manual, and easy t...of this smart material. , ...a future where the only tool in an auto body shop ...
Other Biology Technology:Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 2Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 3Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 4Mach One Corporation Signs Definitive Agreement to Acquire Ceres Organic Harvest, Inc. 2Re-Shaping the Future with Shape Memory Alloys - SMA Starter Kit 2Re-Shaping the Future with Shape Memory Alloys - SMA Starter Kit 3
(Date:11/25/2009)...tate University assistant professors recently rece...(NSF) to continue research beneficial to understan...000. , Christopher Blackwood, assistant professo...arded grants to support two separate research proj...tter Decomposer Communities and Functions from the...
(Date:11/24/2009)...nds of years it has been prescribed by traditional...om headaches and stomach pain to fever and flu. ,...University have been able to scientifically prove ... otherwise known as Brazilian mint. , Testing thi...d by researcher Graciela Rocha was able to show th...
(Date:11/24/2009)...ence is opening new doors to understanding how sou...aring of a marine mammal or if they hear it at al...ay scanners that NASA uses to detect flaws in the ... allowing scientists to peek inside the giant head...e-dimensional replicas of a whale,s hearing anatom...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2Got a pain? -- Have a cup of Brazilian mint 2Rocket science leads to new whale discovery 2Highmarks Online Tool Helps Consumers Compare Costs for Elective Surgeries 54333 1Highmarks Online Tool Helps Consumers Compare Costs for Elective Surgeries 54333 2Hard To Treat Diseases 28HTDS PK 29 Completes IP Ownership Filings With U S Patent and Trademark Office 54328 1Hard To Treat Diseases 28HTDS PK 29 Completes IP Ownership Filings With U S Patent and Trademark Office 54328 2Hard To Treat Diseases 28HTDS PK 29 Completes IP Ownership Filings With U S Patent and Trademark Office 54328 3Hard To Treat Diseases 28HTDS PK 29 Completes IP Ownership Filings With U S Patent and Trademark Office 54328 4Verizon Wireless Offers Healthy Applications to Turn a Mobile Phone Into a Personal Trainer 54323 1Verizon Wireless Offers Healthy Applications to Turn a Mobile Phone Into a Personal Trainer 54323 2
...l component of the human immunodeficiency virus (H...g cells consists of functionally-specialized layer...iversity of California San Diego (UCSD) Antiviral ...LoS Computational Biology. , The unprecedented ... far foiled the best efforts to eradicate the glob...
...get the moo-moo here and quack-quack there. Farmer...za. , And water may be the drop in the bucket tha...al interests, according to research by the Texas A...pplying less water to certain vegetables in the fa...ls, or nutrients, for which consumers may one day ...
... Conn. The gigantic fossil claw of an 390 million... shows that ancient arthropods spiders, insects, ...their modern-day counterparts. , Imagine an eight...ctoral associate in the Department of Geology and...online in Royal Society Biology Letters. The claw ...
Other Biology News:Old McDonald had a phytochemical 2Old McDonald had a phytochemical 3
4300 DNA Analysis System from LI-COR Biosciences
Mouse Anti-Human SCGB3A2 Monoclonal Antibody, Unconjugated, Clone 1B2 from Abnova Corporation
Mouse Anti-Human QPCT Polyclonal Antibody, Unconjugated from Abnova Corporation
...S are multi-functional mixing devices. Stepping mo...solid, heavy-duty durable shaker to provide a unif...ture. Regulated action scale for all modes. Microp...rol time, continuous time, action scale and speed....
Biology Products: